Gregory A. Curt

6.7k total citations · 4 hit papers
62 papers, 5.3k citations indexed

About

Gregory A. Curt is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gregory A. Curt has authored 62 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gregory A. Curt's work include Cancer Treatment and Pharmacology (8 papers), Cancer survivorship and care (8 papers) and Cancer therapeutics and mechanisms (6 papers). Gregory A. Curt is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer survivorship and care (8 papers) and Cancer therapeutics and mechanisms (6 papers). Gregory A. Curt collaborates with scholars based in United States, United Kingdom and Malaysia. Gregory A. Curt's co-authors include David Cella, William Breitbart, Bruce A. Chabner, Jacques Jolivet, Neil J. Clendeninn, Sandra J. Horning, Jerome E. Groopman, Russell K. Portenoy, Nicholas J. Vogelzang and Loretta M. Itri and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Gregory A. Curt

60 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

2000 979 citations Gregory A. Curt, William Breitbart et al. The Oncologist profile →
The Pharmacology and Clinical Use of Methotrexate

1983 646 citations Kenneth H. Cowan, Gregory A. Curt et al. profile →
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.

1997 625 citations William Breitbart, David Cella et al. profile →
Polyglutamation of methotrexate. Is methotrexate a prodrug?

1985 390 citations Bruce A. Chabner, Carmen J. Allegra et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory A. Curt United States	28	2.5k	1.2k	1.0k	970	845	62	5.3k
Mikael Rørth Denmark	49	2.5k 1.0×	1.1k 0.9×	1.4k 1.4×	1.5k 1.5×	605 0.7×	180	6.8k
Loretta M. Itri United States	38	4.0k 1.6×	1.2k 1.0×	1.5k 1.4×	3.5k 3.6×	566 0.7×	91	10.9k
Paul J. Hesketh United States	51	2.4k 1.0×	1.4k 1.2×	1.6k 1.6×	598 0.6×	412 0.5×	161	11.5k
Karin Jordan Germany	33	4.1k 1.6×	606 0.5×	1.4k 1.3×	729 0.8×	493 0.6×	112	7.4k
Steven M. Grunberg United States	50	2.2k 0.9×	986 0.8×	1.5k 1.4×	1.2k 1.2×	365 0.4×	156	9.9k
Aminah Jatoi United States	50	4.6k 1.8×	1.1k 0.9×	2.6k 2.5×	2.4k 2.5×	1.1k 1.3×	400	13.6k
Celeste Lindley United States	33	1.5k 0.6×	621 0.5×	585 0.6×	764 0.8×	303 0.4×	90	5.1k
Jeffrey J. Kirshner United States	35	2.2k 0.9×	327 0.3×	939 0.9×	399 0.4×	402 0.5×	89	5.0k
M L Slevin United Kingdom	38	1.8k 0.7×	626 0.5×	628 0.6×	1.1k 1.2×	785 0.9×	106	4.9k
Wanqing Wen United States	49	2.1k 0.8×	615 0.5×	542 0.5×	2.4k 2.5×	1.8k 2.1×	179	8.2k

Countries citing papers authored by Gregory A. Curt

Since Specialization

Citations

This map shows the geographic impact of Gregory A. Curt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Curt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Curt more than expected).

Fields of papers citing papers by Gregory A. Curt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Curt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Curt. The network helps show where Gregory A. Curt may publish in the future.

Co-authorship network of co-authors of Gregory A. Curt

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Curt. A scholar is included among the top collaborators of Gregory A. Curt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Curt. Gregory A. Curt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

LoRusso, Patricia, Jeffrey R. Infante, Kevin B. Kim, et al.. (2017). A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer. 17(1). 173–173. 15 indexed citations

Infante, Jeffrey R., Roger B. Cohen, Kevin B. Kim, et al.. (2017). A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Investigational New Drugs. 35(5). 576–588. 13 indexed citations

Meyskens, Frank L., Gregory A. Curt, Dean E. Brenner, et al.. (2011). Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research. 4(3). 311–323. 36 indexed citations

Meyskens, Frank L., Gregory A. Curt, Dean E. Brenner, et al.. (2011). Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. - eScholarship. 4(3). 311–323. 1 indexed citations

Fox, Elizabeth, Gregory A. Curt, & Frank M. Balis. (2002). Clinical Trial Design for Target-Based Therapy. The Oncologist. 7(5). 401–409. 95 indexed citations

Sparber, Andrew, et al.. (2001). Use of complementary medicine by adult patients participating in cancer clinical trials [corrected] [published erratum appears in Oncol Nurs Forum 2000 Jul;27(6):888].. Rehabilitation Oncology. 19(2). 30–31. 2 indexed citations

Cella, David, et al.. (2001). Cancer-Related Fatigue: Prevalence of Proposed Diagnostic Criteria in a United States Sample of Cancer Survivors. Journal of Clinical Oncology. 19(14). 3385–3391. 487 indexed citations

Sparber, Andrew, et al.. (2000). Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical Trials. The Journal of Alternative and Complementary Medicine. 6(5). 415–422. 203 indexed citations

Curt, Gregory A.. (2000). The Impact of Fatigue on Patients with Cancer: Overview of FATIGUE 1 and 2. The Oncologist. 5(S2). 9–12. 122 indexed citations

10.

Curt, Gregory A.. (2000). Impact of fatigue on quality of life in oncology patients. Seminars in Hematology. 37(4 Suppl 6). 14–17. 139 indexed citations

11.

Kyle, Edward, Len Neckers, Chris H. Takimoto, Gregory A. Curt, & Raymond C. Bergan. (1997). Genistein-Induced Apoptosis of Prostate Cancer Cells is Preceded by a Specific Decrease in Focal Adhesion Kinase Activity. Molecular Pharmacology. 51(2). 193–200. 148 indexed citations

12.

Yu, Bilian, Jorge A. Carrasquillo, Diane E. Milenic, et al.. (1996). Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.. Journal of Clinical Oncology. 14(6). 1798–1809. 28 indexed citations

13.

Posner, Marshall R., Peter A. Calabresi, I. Brunetti, et al.. (1990). Oral Zidovudine, Continuous-Infusion Fluorouracil, and Oral Leucovorin Calcium: A Phase I Study. JNCI Journal of the National Cancer Institute. 82(21). 1710–1714. 20 indexed citations

14.

Posner, Marshall R., Christopher A. Slapak, Marcia Browne, et al.. (1990). A Phase I-II Trial of Continuous-Infusion Cisplatin, Continuous-Infusion 5-Fluorouracil, and VP-16 in Colorectal Carcinoma. American Journal of Clinical Oncology. 13(5). 455–458. 4 indexed citations

15.

Allegra, Carmen J., Jean Jenkins, Raymond B. Weiss, et al.. (1990). A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infection schedule. Investigational New Drugs. 8(2). 159–166. 9 indexed citations

16.

Fine, Robert L., et al.. (1987). Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs.. Journal of Clinical Oncology. 5(3). 489–495. 31 indexed citations

17.

Lokich, Jacob J. & Gregory A. Curt. (1985). A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration. Cancer. 56(10). 2391–2394. 7 indexed citations

18.

Curt, Gregory A., Kenneth H. Cowan, & B A Chabner. (1984). Gene amplification in drug resistance: of mice and men.. Journal of Clinical Oncology. 2(1). 62–64. 11 indexed citations

19.

Richardson, Vernon J., Gregory A. Curt, & Brenda E. Ryman. (1982). Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro. British Journal of Cancer. 45(4). 559–564. 5 indexed citations

20.

D’Elia, John A., et al.. (1979). Risk of Acute Renal Failure Following Angiography in the Elderly. Angiology. 30(3). 205–207. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact